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1.

Introduction
Current therapeutic options for ureteral stones include active intervention as well as conservative watch and wait approaches. Endoscopic treatment of ureteral stones has a high success rate and reliably results in immediate stone removal [1, 2] ; however, surgical as well as anaesthetic risks are not negligible, and serious complications, although rare, are possible [3] . Thus, for many patients, a conservative treatment without invasive procedures is an appealing option. Watchful waiting, however, does not always result in stone clearance and may be associated with recurrent renal colic [4] . Once a conservative approach proves to be unsuccessful, interventional treatment becomes necessary. After a period of conservative treatment, however, intervention is often inefficient or has a higher risk for complications due to stone impaction and the associated inflammatory reaction of the ureter [5, 6] .
The therapeutic potential of a-blockers for ureteral stone disease has been investigated, prompted by the detection of a-receptors in ureteral smooth muscle cells [7] . Successful medical expulsive therapy (MET) for patients with distal ureteral stones using the nonselective a-blocker doxazosine was first reported in the late 1990 s [8] . Since then, numerous clinical trials have been performed to investigate the efficacy of MET using the 1A/D selective a-blocker tamsulosin alone and in combination with other drugs like corticosteroids and antibiotics [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] . Most of these studies were randomised and revealed that tamsulosin treatment significantly improves the expulsion rate of medium-sized (3-10 mm) distal ureteral stones. Thus, tamsulosin represents a noninvasive and cost-effective alternative to interventional approaches [19] . None of the studies, however, was performed in a double-blind, placebo-controlled fashion.
The objective of this trial was to evaluate the efficacy of MET with tamsulosin for ureteral stones 7 mm in a randomised, double-blind, placebo-controlled setting.
2.
Materials and methods
Participants
This randomised, double-blind, placebo-controlled trial was performed in the Department of Urology at the University Hospital of Zü rich with subjects in an outpatient setting. All male and female patients !18 yr presenting with acute renal colic were evaluated for study participation. Patients with a single ureteral stone 7 mm below the common iliac vessels, as assessed on non-contrast-enhanced abdominal computed tomography (CT), were eligible for the study. Exclusion criteria were the presence of multiple ureteral stones, renal insufficiency (estimated glomerular filtration rate 
Study design
Enrolled patients underwent randomisation in a 1:1 fashion in blocks of 10 to receive either a daily single dose of tamsulosin (0.4 mg) or placebo. The sequence of randomisation was computer generated and was performed by the university hospital pharmacy using DatInf Randlist software v.1.0 (DatInf GmbH, Tü bingen, Germany). Randomisation data were kept strictly confidential in sealed envelopes, accessible only to the primary and senior investigator. Tamsulosin and placebo were provided by the university hospital pharmacy as gelatine capsules of identical appearance and taste and were presented in identical bottles. The patient, the attending urologist, and the investigators were not aware of study arm assignments until the final assessment of outcome.
Sample-size calculation was performed based on previous reports of spontaneous stone expulsion and assumed a clinically relevant difference in expulsion rate of 25% [13, 16, 17, 20] . The stone expulsion rate was estimated to be 90% and 65% for patients with and without tamsulosin medication, respectively. A two-group x 2 test with a twosided significance level of 0.05 will have 80% power to detect the difference between a group 1 proportion of 0.65 and a group 2 proportion of 0.90 when the sample size in each group is 43. Fifty patients per group were finally randomised, which allowed for a maximum drop-out rate of 14%.
The study protocol was approved by the local ethics committee, and the study was performed in accordance with the Declaration of Helsinki.
All enrolled patients provided written informed consent.
Intervention
Patients were requested to take the study medication once at the same time each day and to strain their urine. Furthermore, they kept a diary to record the required amount of analgesic, the score of every painful episode on a 10-cm visual analogue scale, the date and time of stone passage, and the presence and type of side-effects thought to be related to the medication. The study medication was discontinued after spontaneous stone expulsion, intervention, or at the end of the study (ie, after day 21). After initial analgesia for acute pain management, no regular analgesic medication was maintained. Oral diclophenac (up to 3 Â 50 mg) as first-line and oral metamizole (up to 4 Â 1 g) as second-line on-demand analgesics were prescribed.
Follow-up was performed weekly with urinalysis, serum creatinine measurement, abdominal ultrasonography, and, in radiopaque stones, plain abdominal x-ray. Low-dose abdominal CT was performed without knowledge of the treatment allocation to assess the stone status at the end of the study. For patients with a stone-free ureter on final abdominal CT but unnoticed stone expulsion, the date of last positive stone status was recorded. Absence of stone expulsion after day 21 was considered failed therapy. In these cases, continued watchful waiting, ureterorenoscopy (URS), or extracorporeal shock-wave lithotripsy (ESWL) was performed. Discontinuation of study medication and intervention before the end of the study due to uncontrollable pain, adverse events, urinary tract infections, acute renal failure, or the patient's desire for stone removal were also considered failed therapy. These patients were included in the final analysis on an intention-to-treat basis. Patients who experienced stone expulsion before first medication, who withdrew their consent, or who were lost to follow-up were excluded from the analysis.
End points
The primary end point was the proportion of patients experiencing stone expulsion until day 21, as confirmed by low-dose abdominal CT.
Secondary end points were time to stone passage, the required total amount of analgesic, the reported maximum daily pain score until stone expulsion, and the intervention rate, as well as the safety of the therapy. Additionally, factors influencing these end points were assessed.
Statistical analysis
Statistical analysis was performed using R statistical software (R 
Results
From September 2006 to September 2008, a total of 100 patients was randomly assigned to the two treatment arms. Overall, 10 patients were excluded from the final analysis ( Fig. 1) . In eight cases, treatment was discontinued due to adverse events or uncontrollable pain with subsequent intervention (URS or ESWL). No statistically significant differences in age, gender, stone size, and stone location were found between the two treatment arms (Table 1) . Median stone size in the entire population was 3.9 mm (interquartile range [IQR]: 3.5-4.8 mm).
The spontaneous stone expulsion rate within 21 d was not significantly different between the tamsulosin arm (86.7%) and the placebo arm (88.9%; p = 1.0). Univariate analyses revealed that neither the patient's gender and age nor the left/right location of the stone were predictive factors for stone expulsion. The stone location in the ureter, however, had a predictive impact on the stone expulsion rate. The spontaneous expulsion of stones at the ureterovesical junction was significantly higher than of stones in the distal part of the ureter ( p = 0.006). All 11 stones which did not pass spontaneously or required treatment before the end of the study were located in the distal part of the ureter. Furthermore, stone size was significantly smaller in the group of patients with spontaneous stone expulsion ( p = 0.039). The stone expulsion rate was significantly higher for patients with stones 5 mm compared with patients with stones >5 mm ( p = 0.048). The expulsion rate, however, was not significantly different between the treatment arms for patients with stones 5 mm ( p = 1.00) or for those with larger stones ( p = 1.00).
The Kaplan-Meier estimates for time to stone passage are shown in Fig. 2 . A total of 50 patients (56%) were able to define the time of stone expulsion by collecting the stone after urine filtration. Twenty-nine patients (32%) had unnoticed stone expulsion, eight patients (9%) discontinued Table 2 ). The hazard of expulsion at any time was 3-fold higher for stones located at the ureterovesical junction than in the distal part of the ureter. The required total amount of analgesic until stone expulsion was significantly different between the two treatment arms ( p = 0.012). Patients in the tamsulosin arm consumed a median number of three analgesics (IQR: 1-9.8) until stone expulsion, and patients in the placebo arm consumed a median number of seven analgesics (IQR: 4-16) until stone expulsion. Fig. 3 shows the course of the medians of the most painful episodes per day. Only the first 10 d were analysed due to the low number of patients who were at risk after that day.
No severe complications were recorded. Hospital readmissions with consecutive intervention and discontinuation of the medication were due to uncontrollable pain (seven patients) or side-effects (one patient). Six patients (13.3%) in the tamsulosin arm (URS: 4; ESWL: 2) and two patients (4.4%) in the placebo arm (URS: 1; ESWL: 1) required intervention before the end of the study. This difference was statistically nonsignificant ( p = 0.27). None of the patients treated with tamsulosin and three patients (6.7%) treated with placebo failed to expel their stone until day 21. The overall intervention rate was 13.3% in the tamsulosin arm and 8.9% in the placebo arm ( p = 0.74).
Four patients (8.9%) in the tamsulosin arm reported minor side-effects. One patient discontinued therapy due to diarrhoea and subsequently was treated by ESWL. One patient with a mild cutaneous reaction and two patients with retrograde ejaculation continued therapy. In the placebo arm, one patient (2.2%) reported dizziness and inappetence but continued therapy.
Discussion
This first randomised, double-blind, and placebo-controlled trial investigating the efficacy of MET revealed that tamsulosin treatment did not improve the spontaneous expulsion rate of single distal ureteral stones 7 mm. The proportion of patients experiencing stone expulsion within 21 d was slightly but not significantly lower in the tamsulosin arm than in the placebo arm. This finding contrasts with the results of previous clinical trials, which have reported significant improvements in the stone expulsion rate with use of tamsulosin [10] [11] [12] 15] . Two possible reasons that should be highlighted in this context are the actual stone size and the differences in study design between this trial and the previous trials. Stone size has been identified as an important predictive factor for ureteral stone expulsion [20] [21] [22] . The probability for distal ureteral stones to pass spontaneously is as high as 71-98% for stones 5 mm and only 25-51% for stones >5 mm [20, 23, 24] . Approximately 80% of the stones in the present trial were 5 mm. The actual stone size may be a reason for the high stone expulsion rate in the placebo arm. It remains unclear, however, if the lack of improvement of the stone expulsion rate in the tamsulosin arm is also Fig. 3 -Median maximum daily pain-score in the two treatment arms. The pain intensity was slightly higher in the placebo arm until day 4. After the fourth day of treatment, the differences were marginal. 
attributable to the present stone size. The majority of stones in the trials reporting a beneficial effect of tamsulosin on the stone expulsion rate were >5 mm [10, 12, 15, 18] . It is reasonable to assume that the efficacy of MET will be relatively greater for larger stones, as smaller stones are more likely to pass without any treatment. Currently, it is not known whether a potential a-blocker effect on stone expulsion depends on ureteral stone size. In the present trial, patients with stones >5 mm had less chance of passing the stone spontaneously but tamsulosin treatment did not improve the expulsion rate of these stones. Admittedly, the study was not powered for this subgroup analysis; therefore, the value of this analysis is limited. Three meta-analyses have confirmed a positive effect of a-blocker therapy on the stone expulsion rate [25] [26] [27] ; however, important potential confounders have also been pointed out which may affect the validity of the results and may lead to an overestimation of the identified treatment effect [25] [26] [27] [28] . Although most of the published studies were randomised, reporting of randomisation methods was often unclear or even absent, as were placebo treatment and blinding to treatment generally. Furthermore, determination of the stone status by abdominal CT at the end of the study was not performed in most of the previous studies. The differences in study design between the present trial and previous trials may be an additional factor contributing to the different outcomes. Interestingly, in accordance with the results of the present study, the only other double-blind, placebo-controlled study for a-blocker therapy of distal ureteral stones also revealed no improvement in the stone expulsion rate [29] . In that study, the mean stone size was <5 mm, but the non-subtype-selective a-1-receptor blocker alfuzosin was investigated.
The decision for a conservative medical treatment or an active interventional treatment is not based only on the overall probability of stone expulsion. For many patients, factors like time to convalescence or reexposure to dreaded colics during conservative treatment have a considerable impact on the decision to opt for an interventional treatment.
A faster and less painful stone expulsion, regardless of stone size, has constantly been reported with MET [10, 13, 16] . In the present trial, median time to stone passage was 3 d shorter for patients who were treated with tamsulosin than for patients who were treated with placebo. Although this difference may be clinically meaningful, it was statistically nonsignificant.
The secondary end point of total intake of analgesics, however, was significantly different between the treatment arms. Patients in the tamsulosin arm required fewer analgesics until stone expulsion than patients in the placebo arm. This difference may be attributable to the accelerated stone expulsion with a consecutive shorter time at risk for painful events. Additionally, a true analgesic effect of tamsulosin has been reported [30] . The lower maximum pain scores in the tamsulosin arm during the first days support the existence of such an effect. Thus, pain modulation seems to be an important feature of MET with tamsulosin in patients with stones 7 mm.
No serious complications were recorded in either treatment arm. Adverse events of tamsulosin treatment were mild and led to therapy discontinuation in only one patient.
Some limitations of the present trial deserve mention. The smaller stone size in the present trial compared with previous trials makes it difficult to directly compare the results of the different trials. Furthermore, for 32% of the patients, the exact time of stone passage was not available. Thus, these patients needed to be censored at the last known date of stone presence. The secondary end point of time to stone passage is based on Kaplan-Meier estimation.
Conclusions
Patients with single distal ureteral stones 7 mm do not benefit from MET with tamsulosin in terms of an improved expulsion rate. Nevertheless, the generally well-tolerated treatment may be beneficial for these patients due to an analgesic effect and, thus, a reduced need of analgesics until stone expulsion.
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